Category: Novartis

Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Visiongain Reports Ltd Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS…

Continue Reading Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Translational Regenerative Medicine market is estimated to

Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading…

Continue Reading Translational Regenerative Medicine market is estimated to

16 UK biotech companies you should know about

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…

Continue Reading 16 UK biotech companies you should know about

Isomorphic signs drug discovery deals with Eli Lilly and Novartis

The company aims to use the power of AI to tackle various diseases and could receive nearly $3bn from its new research collaborations. DeepMind spin-out Isomorphic Labs has signed two deals with pharma giants to discover new drugs, which could lead to billions in profit for the company. The Alphabet…

Continue Reading Isomorphic signs drug discovery deals with Eli Lilly and Novartis

Novartis pays Isomorphic Labs $37.5 million in collab deal

Isomorphic Labs is a digital biology company that says its mission is to redefine drug discovery using artificial intelligence (AI) and says the collaboration with Novartis is to discover small molecule therapeutics against three undisclosed targets.   “Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and…

Continue Reading Novartis pays Isomorphic Labs $37.5 million in collab deal

Google’s AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery – Alphabet (NASDAQ:GOOG), Alphabet (NASDAQ:GOOGL), Eli Lilly (NYSE:LLY), Novartis (NYSE:NVS)

Isomorphic Labs, a London-based spin-out of Alphabet Inc GOOG GOOGL Google’s AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co LLY and Novartis AG NVS.  These alliances aim to leverage AI to discover new medications to treat diseases.  The combined value of these deals is around $3 billion.  Isomorphic will receive $45 million upfront from Eli Lilly, potentially…

Continue Reading Google’s AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery – Alphabet (NASDAQ:GOOG), Alphabet (NASDAQ:GOOGL), Eli Lilly (NYSE:LLY), Novartis (NYSE:NVS)

2 low-priced gene therapy stocks to speculate on

Key Points bluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share. bluebird bio’s latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per…

Continue Reading 2 low-priced gene therapy stocks to speculate on

80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Job Category Any CategoryJobInternshipWork from Home Job Type Any Job TypesFull-timePart-timeContractVolunteer Location Any CountryUKCanadaAustraliaPakistanIrelandGermanyUSASwedenNew ZealandMalaysiaRussiaNetherlandDubaiSwitzerlandJapanVietnamItalyDenmarkOnlineGeorgiaLatviaSingaporeChinaNetherlandsIndiaFranceBelgiumBrazilColombiaEuropeEstoniaThailandNorwayNigeriaQatarCambodiaUAESouth KoreaAustriaTurkeyworldwideADB CountriesIndonesiaSaudi Arabia Industry Any Industry athletic apparel and footwear Refugee AgencyAccredited registrarAeronauticsAerospaceAirlineappliance manufacturerArtificial Intelligencearts, entertainment, and recreation sectorAstronomical ResearchAutomationAutomativeAviationBankingBioinformaticsBroadcastingBusiness Administrationcar manufacturingchemicalCivic and Social OrganizationsCivil EngineeringConsumer goodsCreativity and Innovation DevelopmentCyber SecurityDairyingData analyticsDevelopmentDigitale-commerceEducationEducationElectric Power GenerationEnergyEngineeringEngineering Professional…

Continue Reading 80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Data Scientist / Bioinformatician, Biologics R&D Job

Job Description 6000! This is the number of associates in the Novartis Institutes for BioMedical Research (NIBR). This division is the innovation engine of Novartis, focusing on new technologies that have the potential to help produce therapeutic breakthroughs for patients. The Biologics Center (NBC) is accommodated within the Novartis Institutes…

Continue Reading Data Scientist / Bioinformatician, Biologics R&D Job

ASH 2023: Lymphoma Studies May Inform Practice

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Continue Reading ASH 2023: Lymphoma Studies May Inform Practice

Viral Vectors and Plasmid DNA Manufacturing market is

Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), by Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), by End-use (Pharma and Biopharma Companies, Research Institutes), by Disease (Oncology, Genetic Disorders,…

Continue Reading Viral Vectors and Plasmid DNA Manufacturing market is

Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well the drug will match up against a radiopharmaceutical marketed by Novartis. The Point drug,…

Continue Reading Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind. Pharma and…

Continue Reading 3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Programmable Genomic Integration Company Raises Over $200 Million

Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised…

Continue Reading Programmable Genomic Integration Company Raises Over $200 Million

CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

(MENAFN– The Express Wire) The Global “CAR-T Cell Immunotherapies for Cancer Market ” Growth Forecast Report 20242031 is an essential tool for understanding the growth strategies, and various segments of industry by Type [ CD19, BCMA, EPCAM ] and Applications [ Hematological Cancer, Solid Tumor, Other Oncological Disorders ]. The…

Continue Reading CAR-T Cell Immunotherapies For Cancer Market Analysis 2024: Business Share And Size Forecast By Regions Till 2031

Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators…

Continue Reading Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Seven precision medicine companies worth keeping an eye on

Precision medicine is an approach to tailoring treatments based on people’s genetic makeup, lifestyles and environment. These targeted interventions can tackle diseases like cancer, neurological as well as metabolic diseases. The global market value of the precision medicine industry, encompassing many companies, crossed 70 billion last year, and is expected…

Continue Reading Seven precision medicine companies worth keeping an eye on

U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the…

Continue Reading U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…

Continue Reading Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

Can sickle cell one day be treated not with CRISPR, but with pills?

Two gene therapies were approved for sickle cell disease last week, but for many researchers the Holy Grail remains something far more modest: A pill. Only the pharmacists’ oldest tool, they say, can actually have an impact on the scale of sickle cell. The gene therapies, with the risks and…

Continue Reading Can sickle cell one day be treated not with CRISPR, but with pills?

Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Introduction Reproxalap, a novel chemical entity in late-stage clinical development for the treatment of ocular inflammation, chemically sequesters a class of small molecules known as reactive aldehyde species (RASP). Via covalent binding to amine and thiol residues, RASP modulate the structure and function of proteins in an analog manner1 depending…

Continue Reading Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Measurable Residual Disease-Guided Therapy Promising in CLL

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

Continue Reading Measurable Residual Disease-Guided Therapy Promising in CLL

RNAi Technology Market is expected to reach US$ 3.6 billion by 2030

The field of RNA interference (RNAi) is witnessing significant growth with the approval of small interfering RNA (siRNA) drugs by the US FDA. These siRNA therapeutics offer a powerful and specific approach to target mRNA, with notable approvals like Patisiran, Givosiran, Lumasiran, Inclisiran, and Vutrisiran. The liver has been a…

Continue Reading RNAi Technology Market is expected to reach US$ 3.6 billion by 2030

Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

What is Fibroblast Growth Factor Receptor 2 Inhibitor? Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitors have emerged as a promising therapeutic class in the field of precision medicine, particularly in the treatment of certain types of cancer. These inhibitors selectively target the FGFR2 signaling pathway, which is responsible for stimulating…

Continue Reading Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Value and Report 2023-2030

The forecasted growth in the treatment of Diffuse Large B-cell Lymphoma (DLBCL) is driven by the increasing preference for targeted therapies. Targeted therapies, such as monoclonal antibodies and kinase inhibitors, offer a less toxic alternative to chemotherapy by focusing on specific molecular targets associated with cancer. Notable examples include rituximab…

Continue Reading Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Value and Report 2023-2030

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform Technology, in-licensed from the Massachusetts Institute of Technology (MIT), capable of inserting DNA sequences of any size into any programmed genomic location Potential to create curative cell and integrative gene therapies Backed by leading biotech…

Continue Reading Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Iptacopan: A New Milestone in Rare Disease Treatment

The pharmaceutical industry has reached a new milestone with the advent of a promising drug, Iptacopan (also known as Fabhalta), developed by Novartis. The company has recently reported positive topline results from a phase 3 trial of this drug, which is designed to treat a rare kidney disease known as…

Continue Reading Iptacopan: A New Milestone in Rare Disease Treatment

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO,…

Continue Reading Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Novartis reports success in phase 3 trial of drug for rare kidney disease

Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease. Patients with the kidney disease, C3 glomerulopathy, who were taking 200 mg of iptacopan — also called Fabhalta — twice daily for six months were…

Continue Reading Novartis reports success in phase 3 trial of drug for rare kidney disease

Promising Fabhalta data for C3 glomerulopathy indication

Novartis released promising data on Fabhalta (iptacopan), its recently approved drug for paroxysmal nocturnal hemoglobinuria, this time for a new indication — a rare disease called C3 glomerulopathy (C3G). Topline results from a Phase 3 study released Monday morning showed that iptacopan met its primary endpoint and was effective in…

Continue Reading Promising Fabhalta data for C3 glomerulopathy indication

how to obtain a valid patent?

The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process…

Continue Reading how to obtain a valid patent?

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Results from the PARSIFAL-LONG study investigating endocrine-sensitive hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer demonstrated the efficacy of 2 combined option therapies, palbociclib (Ibrance; Pfizer) plus letrozole (Femara; Novartis) and palbociclib plus fulvestrant (Faslodex; Hikma), as first-line treatments for metastatic breast cancer. The study found no significant differences in progression-free survival…

Continue Reading No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Gene Therapy Market estimated to grow according to forecasts

Allied Market Research has published a study report Gene Therapy Market Size is Anticipated to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% Allied Market Research published a report, titled, “Gene Therapy Marketby Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by…

Continue Reading Gene Therapy Market estimated to grow according to forecasts

Blau syndrome Market Scope and overview

Blau syndrome Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report provides an overview including definitions, applications, product launches, developments, challenges, and regions. It is predicted that the market will show strong development due to the driven consumption in various…

Continue Reading Blau syndrome Market Scope and overview

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

Continue Reading Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

FDA OKs Iptacopan to Treat Paroxysmal Nocturnal Hemoglobinuria

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta, Novartis), the first oral monotherapy for both treatment-naive and pretreated adults with paroxysmal nocturnal hemoglobinuria (PNH).  Iptacopan, a factor B inhibitor, offers “superior hemoglobin improvement in the absence of transfusions” in patients with this rare chronic blood disorder, according…

Continue Reading FDA OKs Iptacopan to Treat Paroxysmal Nocturnal Hemoglobinuria

Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market Key Business Opportunities, Impressive Growth Rate and Analysis to 2030 | by Vikashundekar | Dec, 2023

The report furnishes a comprehensive analysis of the Global Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market for 2023, encompassing global, regional, and country-specific dimensions. It covers various aspects, including market sizes, segmentation market growth, competitive landscape, market share, sales analysis, and the influence of both domestic and global players in…

Continue Reading Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market Key Business Opportunities, Impressive Growth Rate and Analysis to 2030 | by Vikashundekar | Dec, 2023

Merck KGaA’s highly anticipated MS drug fails in Phase 3 trial

Merck KGaA’s highly anticipated experimental multiple sclerosis (MS) drug failed to meet its primary endpoint in two Phase 3 trials, the company announced this week. The EVOLUTION trials found that the drug, evobrutinib, didn’t meet its primary endpoint of reducing annualized relapse rates in patients with relapsing MS compared to…

Continue Reading Merck KGaA’s highly anticipated MS drug fails in Phase 3 trial

Gene Therapy Market projected to reach USD 38.33 Billion by

Richmond, Dec. 06, 2023 (GLOBE NEWSWIRE) — According to a research report “Gene Therapy Market”, By Technology (Viral Vector-Based Gene Therapy {Adeno-Associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus and Modified Herpes Simplex Virus}, Non-Viral Vectors-Based Gene Therapy {Electroporation, Gene Gun, Liposomes and Naked DNA}, CRISPR/Cas9 Technology), Therapy Type (Acute Lymphoblastic Leukemia…

Continue Reading Gene Therapy Market projected to reach USD 38.33 Billion by

Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

PRESS RELEASE Published December 6, 2023 DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by…

Continue Reading Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. Stanford is currently accepting patients for this trial. Eligibility Inclusion Criteria: Patients eligible for…

Continue Reading CTL019 Out of Specification MAP for ALL or DLBCL Patients

Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…

Continue Reading Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

What does it mean for oncology and beyond?

Chimeric antigen receptor (CAR) T-cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR T-cell…

Continue Reading What does it mean for oncology and beyond?

Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

Market Overview and Report Coverage Fibroblast Growth Factor Receptor 2 (FGFR2) is a protein found on the surface of cells that plays a crucial role in cell growth, division, and differentiation. It is a receptor for fibroblast growth factors (FGFs), which are a group of proteins responsible for controlling various…

Continue Reading Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

DNA Nanotechnology Market Global Report

Statsndata’s DNA Nanotechnology Market research reports provide all the information. It fuels market growth by providing customers with reliable data that helps them make critical decisions. Get a sample report:www.statsndata.org/download-sample.php?id=15160 Provides an overview including market, definition, applications and developments, and manufacturing technology. This DNA Nanotechnology market research report tracks all…

Continue Reading DNA Nanotechnology Market Global Report

Ny tantaran’i Kim – DLBCL & CAR T-cell therapy

Tamin’ny Septambra 2020, i Kim dia voan’ny Lymphoma B-Cell Diffuse Large. Indrisy anefa fa tsy namaly ny fitsaboana tamin’ny voalohany i Kim. Ny ekipany ao amin’ny Hopitaly PA any Brisbane dia afaka nanondro azy ho any amin’ny ekipa mpitrandraka ao amin’ny RBWH mba hidirana amin’ny fitsaboana T-cell CAR vaovao. Hatramin’ny…

Continue Reading Ny tantaran’i Kim – DLBCL & CAR T-cell therapy

Car T Cell Therapy Market will generate new growth opportunities 2023-2030

PRESS RELEASE Published November 29, 2023 The research study conducted by Coherent Market Insights on the “Car T Cell Therapy Market” spans over 100 pages and delves into various facets of this market. It analyzes the business strategies adopted by emerging industry players, examines the geographical scope, dissects market segments,…

Continue Reading Car T Cell Therapy Market will generate new growth opportunities 2023-2030

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Abstract A major unmet need in the cystic fibrosis (CF) therapeutic landscape is the lack of effective treatments for nonsense CFTR mutations, which affect approximately 10% of CF patients. Correction of nonsense CFTR mutations via genomic editing represents a promising therapeutic approach. In this study, we tested whether prime editing,…

Continue Reading Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Small Interfering RNA Market revenue to hit USD 67 Billion by 2036, says Research Nester

Research Nester Key small interfering rna market players include GE HealthCare Technologies, Inc., Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis AG. New York , Nov. 29, 2023 (GLOBE NEWSWIRE) — The global small interfering rna (sirna) …

Continue Reading Small Interfering RNA Market revenue to hit USD 67 Billion by 2036, says Research Nester

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

Blenrep redux? New Phase 3 data revive interest in GSK blood cancer drug – MM+M

GSK blood cancer drug Blenrep, withdrawn from the U.S. market just 12 months ago, may see renewed interest thanks to positive data from a combination trial. The Phase 3 study, dubbed DREAMM-7, showed that Blenrep, a BCMA-directed antibody drug conjugate (ADC), significantly extended the time to disease progression or death…

Continue Reading Blenrep redux? New Phase 3 data revive interest in GSK blood cancer drug – MM+M

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

For Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Inc. LGND. Industry: Biotech Link: www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright It has been a choppy ride for the biotech industry in 2023…

Continue Reading Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

Global Diffuse Large B-cell Lymphoma Therapeutics Market

Global Diffuse Large B-cell Lymphoma Therapeutics Market Forecast 2023-2032 The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies the increasing incidence…

Continue Reading Global Diffuse Large B-cell Lymphoma Therapeutics Market

A Deep Dive into Trends, Players, and Growth

The gene therapy market has evolved into a juggernaut in the healthcare sector, displaying an extraordinary trajectory of growth. As of 2023, the gene therapy market has surged to a remarkable value of USD 6.36 billion, and the projection for the forthcoming years is nothing short of astonishing. Forecasts indicate…

Continue Reading A Deep Dive into Trends, Players, and Growth

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

CRISPR therapies Pipeline Insights 2023: Therapies, Latest

CRISPR therapies Pipeline (New York, USA) “CRISPR therapies Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market. The CRISPR therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental…

Continue Reading CRISPR therapies Pipeline Insights 2023: Therapies, Latest

Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease

In a landmark announcement for the CRISPR field and the sickle cell disease (SCD) community, the U.K. authorities have granted approval to Casgevy, the CRISPR-Cas9 therapy formerly known as exa-cel developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The U.S. Food and Drug Administration (FDA) is expected to follow suit in…

Continue Reading Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease

Gene Therapy Market Size Worth US$ 16.8 Billion, Globally, by 2032 – Exclusive Report by IMARC Group

The global gene therapy market size reached US$ 5.1 Billion in 2023. By 2032, it will reach a value of US$ 16.8 Billion, growing at a CAGR of 13.9% (2024-2032). SHERIDAN, WYOMING, USA, November 16, 2023 /EINPresswire.com/ — How Big is the Gene Therapy Market? The global gene therapy market…

Continue Reading Gene Therapy Market Size Worth US$ 16.8 Billion, Globally, by 2032 – Exclusive Report by IMARC Group

Activist Investor Reported to Take $1B Stake in BioMarin

GEN Edge presents Gene Therapy Briefs, a roundup of commercial developments in gene therapy and other genome editing technologies. Gene Therapy Briefs has long appeared in the journal Human Gene Therapy, published by GEN publisher Mary Ann Liebert Inc., publishers. Elliott Investment Management, a fund manager with approximately $60 billion…

Continue Reading Activist Investor Reported to Take $1B Stake in BioMarin

Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase (BTK) inhibitor, showed promising results in the treatment of chronic spontaneous urticaria (CSU) in the phase 3 REMIX-1 and REMIX-2 studies, according to a press release from Novartis. The findings were presented as a late-breaking abstract at the 2023 American College of Allergy,…

Continue Reading Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials

How Will the Market React to Intellia Therapeutics Inc (NTLA) Stock Getting a Bearish Rating

News Home Tuesday, November 14, 2023 10:04 AM | InvestorsObserver Analysts Mentioned in this article The market has been down on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bearish sentiment reading. Find out what this means…

Continue Reading How Will the Market React to Intellia Therapeutics Inc (NTLA) Stock Getting a Bearish Rating

Genetic Engineering Market: Beating Growth Expectations | Illumina, CRISPR Therapeutics, Merck

According to HTF Market Intelligence, the Global Genetic Engineering market to witness a CAGR of 24.2% during the forecast period (2023-2029). The Latest Released Genetic Engineering Market Research assesses the future growth potential of the Genetic Engineering market and provides information and useful statistics on market structure and size. This…

Continue Reading Genetic Engineering Market: Beating Growth Expectations | Illumina, CRISPR Therapeutics, Merck

Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug

In an early phase multicenter clinical study, large reductions in lipoprotein(a), or Lp(a), were achieved with a well-tolerated small interfering RNA (siRNA) therapeutic, lepodisiran. The reductions in serum Lp(a) in patients receiving lepodisiran were dose dependent but adverse events were not, said Steven E. Nissen, MD, professor of medicine at…

Continue Reading Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

A single injection cut Lp(a) by 94% at 48 weeks and was well tolerated, findings that researchers say justify further studies. Lepodisiran, a long-duration, short-interfering RNA (siRNA), dramatically slashed Lp(a) levels in a small, phase I study presented this weekend at the American Heart Association (AHA) 2023 Scientific Sessions. Lead…

Continue Reading Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma

Review doi: 10.1016/j.blre.2023.101140. Online ahead of print. Affiliations Expand Affiliations 1 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America. 2 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America; Case Comprehensive Cancer Center, Cleveland, OH,…

Continue Reading A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

CAR T Cell Therapy Market Demands, Industry Analysis and Forecast 2032 | Taiwan News

Report Ocean has recently published a revised figures report on the worldwide CAR T Cell Therapy market. Growth prospects and difficulties are noted in the paper. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting…

Continue Reading CAR T Cell Therapy Market Demands, Industry Analysis and Forecast 2032 | Taiwan News

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

Continue Reading Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Cloves Syndrome Market Share And Industry Trends 2023-2030

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Increasing Funding, and Availability of Targeted Treatments. Cloves Syndrome Market Outlook Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevis, Spinal/Skeletal Anomalies/Scoliosis (CLOVES) syndrome is a very rare congenital (present at birth) disorder characterized by a combination…

Continue Reading Cloves Syndrome Market Share And Industry Trends 2023-2030

Genmab Announces Financial Results for the First Nine

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy Epcoritamab…

Continue Reading Genmab Announces Financial Results for the First Nine

Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds

Only one biologic drug is approved for treating the hives and itchy rash caused by chronic spontaneous urticaria, an inflammatory skin disorder. Celldex Therapeutics’ lead program is shaping up as a viable and potentially superior alternative. The biotech reported preliminary Phase 2 data on Monday, showing its biologic, barzolvolimab, met…

Continue Reading Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds

Molecular Diagnostics Rapidly Growing Market Globally

[New York, November 2023] — An insightful market analysis report focusing on the Molecular Diagnostics Market has just been released by StatsNData, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Molecular Diagnostics market and its subsegments, providing…

Continue Reading Molecular Diagnostics Rapidly Growing Market Globally

BioTechX 2023: the highlights

BioTechX 2023, one of Europe’s largest conventions, that blends diagnostics, precision medicine and digital transformation in the field of healthcare, took place in the biotech hub of Basel, Switzerland. The event, which was held from October 4 to 6, hosted expert panelists who shared their knowledge on the digital transformation…

Continue Reading BioTechX 2023: the highlights

2023-11-01 | NDAQ:SGMO | Press Release

Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. Dosed a total of 25 patients in Phase 1/2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional…

Continue Reading 2023-11-01 | NDAQ:SGMO | Press Release

A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Latest Trends Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors are drugs that work by inhibiting the activity of the FGFR2 receptor, which plays a crucial role in cell growth, differentiation, and embryonic development. These inhibitors are primarily used in the treatment…

Continue Reading A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

Global Gene Therapy Market Poised for Remarkable 9.26% CAGR, Expected to Reach USD 10.13 Billion by 2028

Company Logo Gene Therapy Market Gene Therapy Market Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) — The “Gene Therapy Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com‘s offering. The global Gene Therapy Market, valued at USD 6.01 billion in 2022, is set…

Continue Reading Global Gene Therapy Market Poised for Remarkable 9.26% CAGR, Expected to Reach USD 10.13 Billion by 2028

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data | GigaScience

Abstract Low-level mosaic epimutations within the BRCA1 gene promoter occur in 5–8% of healthy individuals and are associated with a significantly elevated risk of breast and ovarian cancer. Similar events may also affect other tumor suppressor genes, potentially being a significant contributor to cancer burden. While this opens a new…

Continue Reading epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data | GigaScience

Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned

Novartis’s $3.2 billion acquisition of Chinook Therapeutics brought two drug prospects for a chronic kidney disorder with few approved treatments. One of these newly acquired drugs has now met the main goal of its Phase 3 test, results the Swiss pharmaceutical said will support plans to seek accelerated FDA approval…

Continue Reading Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned

177Lu-PSMA-617 drug shortage is resolved, FDA determines

The FDA has marked the 177Lu-PSMA-617 (Pluvicto) drug shortage status as resolved given unconstrained supply of the prostate cancer agent, announced Novartis, the developer of the therapy, in a news release.1 177Lu-PSMA-617 was approved in 2022 based on findings from the phase 3 VISION trial. According to the release, Novartis…

Continue Reading 177Lu-PSMA-617 drug shortage is resolved, FDA determines

Atrasentan Achieves Positive Topline Results in Phase 3 Trial for IgA Nephropathy

Shreeram Aradhye, MD Credit: Novartis Novartis has announced positive topline results from a 36-week interim analysis of the Phase 3 ALIGN study for atrasentan in patients with immunoglobulin A (IgA) nephropathy. Announced on October 30, 2023, the study met its primary efficacy endpoint of superiority compared to placebo for reduction…

Continue Reading Atrasentan Achieves Positive Topline Results in Phase 3 Trial for IgA Nephropathy

Novartis to Seek US Accelerated Approval of Atrasentan After Phase 3 Study Met Primary Goal

By Giulia Petroni Novartis will submit an application next year for a possible accelerated approval of atrasentan in the U.S. after its phase 3 study met the primary endpoint. The Swiss pharmaceutical company said Monday that the study showed a significant reduction in proteinuria, a condition causing high levels of…

Continue Reading Novartis to Seek US Accelerated Approval of Atrasentan After Phase 3 Study Met Primary Goal

Nucleic Acid Testing Market Thriving Worldwide: Abbott Laboratories, Beckman Coulter, Illumina

According to HTF Market Intelligence, the Global Nucleic Acid Testing market to witness a CAGR of 8.4% during forecast period of 2023-2028. The market is segmented by Nucleic Acid Testing Comprehensive Study by Type (Nucleic Acid Test Kits, Consumables), Nucleic Acid Test Kits (Ligase Chain Reaction (LCR), Transcription–mediated Amplification (TMA),…

Continue Reading Nucleic Acid Testing Market Thriving Worldwide: Abbott Laboratories, Beckman Coulter, Illumina

major antitrust cases in recent years

Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby…

Continue Reading major antitrust cases in recent years

Lupus Therapeutics, AbbVie team up for upadacitinib Phase 3 trial

Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the accelerated evaluation of upadacitinib as a potential treatment for individuals living with SLE,” Stacie Bell, PhD, Lupus Therapeutics’ executive vice president, said…

Continue Reading Lupus Therapeutics, AbbVie team up for upadacitinib Phase 3 trial

Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

October 26, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

[Latest] Global DNA Repair Drugs Market to be Worth USD 10.4 billion by 2031 | Transparency Market Research Inc.

DNA Repair Drugs Market Rise in incidence of cancer and advancements in DNA sequencing technologies WILMINGTON, DELAWARE, UNITED STATES, October 26, 2023 /EINPresswire.com/ — The global DNA repair drugs market offers a unique insight into key trends shaping the industry world-wide and in the largest markets. Written by some…

Continue Reading [Latest] Global DNA Repair Drugs Market to be Worth USD 10.4 billion by 2031 | Transparency Market Research Inc.

Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine -October 25, 2023 at 05:20 pm EDT

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

Continue Reading Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine -October 25, 2023 at 05:20 pm EDT

2023-10-25 | NDAQ:ALNY | Press Release

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

Continue Reading 2023-10-25 | NDAQ:ALNY | Press Release

Phase 3 Trial Results Show Lutetium Can Reduce Risk of Disease Progression in Patients With Prostate Cancer

Data from the phase 3 clinical trial PSMAfore (NCT04689828) show lutetium (Pluvicto; Novartis) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen receptor pathway inhibitor (ARPI)…

Continue Reading Phase 3 Trial Results Show Lutetium Can Reduce Risk of Disease Progression in Patients With Prostate Cancer

Global Epigenetics Market : Report Position, Recent Developments, Trends and Future Forecast 2023 to 2028

Research by the Global Market Studies has reported a CAGR of 13.5% for the Global Epigenetics Market, expecting to surpass the USD 3 billion mark by 2028. LAS VEGAS, NEVADA, UNITED STATES, October 24, 2023 /EINPresswire.com/ — Research by the Global Market Studies has reported a CAGR of 13.5% for…

Continue Reading Global Epigenetics Market : Report Position, Recent Developments, Trends and Future Forecast 2023 to 2028

Global Molecular Diagnostics Market Set to Soar: Projected

Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) — The “Molecular Diagnostics Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease Area, Technology, Product & Services, End User, and Geography” report has been added to ResearchAndMarkets.com‘s offering. The global molecular diagnostics market is…

Continue Reading Global Molecular Diagnostics Market Set to Soar: Projected

Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality

Experimental design Primary T cell isolation, expansion, and cell culture Primary T cells were isolated from human peripheral blood mononuclear cells (PBMCs) of healthy donors collected by the Institute for Transfusion Medicine of the University Clinic of Leipzig, Germany, approved by the Ethics Committee of the Faculty of Medicine of…

Continue Reading Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality

Planet Microbe

The pioneering cartographer of the human genome, Craig Venter, discusses synthetic biology and his new book, “Sorcerer II: The Expedition That Unlocked The Secrets of The Ocean’s Biome” with Noema Editor-in-Chief Nathan Gardels. Nathan Gardels: Generative AI has been heralded lately as one of the great game-changing innovations of our…

Continue Reading Planet Microbe

How CRISPR Companies Target Sickle Cell Anemia

A Crippling And Painful Disease Sickle Cell Disease (SCD) is a blood disease caused by a genetic mutation. This mutation creates abnormal hemoglobin, the protein carrying oxygen in the blood’s red cells. As a result, red cells are shaped like sickles and tend to get stuck in blood vessels, causing…

Continue Reading How CRISPR Companies Target Sickle Cell Anemia

Phase 3 innovaTV 301 Trial Shows Potential of Tisotumab Vedotin in Cervical Cancer

Ignace B. Vergote, MD, PhD In the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628), tisotumab vedotin-tftv (Tivdak) demonstrated a 30% reduction in the risk of death compared with investigator’s choice of chemotherapy when utilized in the second- or third-line for patients with recurrent or metastatic cervical cancer with disease progression on…

Continue Reading Phase 3 innovaTV 301 Trial Shows Potential of Tisotumab Vedotin in Cervical Cancer

SoftMaskedAlphabet.CaseSensitiveTokenization (BioJava-1.7 API)

SoftMaskedAlphabet.CaseSensitiveTokenization (BioJava-1.7 API)  PREV CLASS   NEXT CLASS FRAMES    NO FRAMES     All Classes SUMMARY: NESTED | FIELD | CONSTR | METHOD DETAIL: FIELD | CONSTR | METHOD org.biojava.bio.symbol Class SoftMaskedAlphabet.CaseSensitiveTokenization java.lang.Object org.biojava.utils.Unchangeable org.biojava.bio.symbol.SoftMaskedAlphabet.CaseSensitiveTokenization All Implemented Interfaces: Annotatable, SymbolTokenization, Changeable Enclosing class: SoftMaskedAlphabet public class SoftMaskedAlphabet.CaseSensitiveTokenization extends Unchangeable implements SymbolTokenization This SymbolTokenizer works with a delegate to softmask symbol tokenization as…

Continue Reading SoftMaskedAlphabet.CaseSensitiveTokenization (BioJava-1.7 API)